The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AADI BIOSCIENCES INC | Common | 00032Q104 | 19,489,910 | 2,849,402 | SH | SOLE | 2,849,402 | 0 | 0 | ||
AEGLEA BIOTHERAPEUTICS INC | Common | 00773J103 | 129,050 | 286,459 | SH | SOLE | 286,459 | 0 | 0 | ||
ALNYLAM PHARMACEUTICALS INC | Common | 02043Q107 | 209,883,700 | 1,105,000 | SH | SOLE | 1,105,000 | 0 | 0 | ||
AMICUS THERAPEUTICS INC | Common | 03152W109 | 344,144,000 | 27,400,000 | SH | SOLE | 27,400,000 | 0 | 0 | ||
APELLIS PHARMACEUTICALS INC | Common | 03753U106 | 1,012,222,212 | 11,111,111 | SH | SOLE | 11,111,111 | 0 | 0 | ||
ARGENX SE | Sponsored ADR | 04016X101 | 492,423,855 | 1,263,500 | SH | SOLE | 1,263,500 | 0 | 0 | ||
ARROWHEAD PHARMACEUTICALS INC | Common | 04280A100 | 12,744,991 | 357,403 | SH | SOLE | 357,403 | 0 | 0 | ||
ASCENDIS PHARMA | Sponsored ADR | 04351P101 | 319,564,534 | 3,580,555 | SH | SOLE | 3,580,555 | 0 | 0 | ||
AVIDITY BIOSCIENCES INC | Common | 05370A108 | 27,835,900 | 2,510,000 | SH | SOLE | 2,510,000 | 0 | 0 | ||
BIOCRYST PHARMACEUTICALS INC | Common | 09058V103 | 84,867,200 | 12,055,000 | SH | SOLE | 12,055,000 | 0 | 0 | ||
BIOMARIN PHARMACEUTICAL INC | Common | 09061G101 | 346,720,000 | 4,000,000 | SH | SOLE | 4,000,000 | 0 | 0 | ||
CYMABAY THERAPEUTICS INC | Common | 23257D103 | 112,785,000 | 10,300,000 | SH | SOLE | 10,300,000 | 0 | 0 | ||
DESIGN THERAPEUTICS INC | Common | 25056L103 | 22,050,000 | 3,500,000 | SH | SOLE | 3,500,000 | 0 | 0 | ||
DICE THERAPEUTICS INC | Common | 23345J104 | 102,181,429 | 2,199,342 | SH | SOLE | 2,199,342 | 0 | 0 | ||
FENNEC PHARMACEUTICALS INC | Common | 31447P100 | 10,596,000 | 1,200,000 | SH | SOLE | 1,200,000 | 0 | 0 | ||
HORIZON THERAPEUTICS PLC | Common | G46188101 | 719,950,000 | 7,000,000 | SH | SOLE | 7,000,000 | 0 | 0 | ||
IKENA ONCOLOGY INC | Common | 45175G108 | 10,758,400 | 1,640,000 | SH | SOLE | 1,640,000 | 0 | 0 | ||
IO BIOTECH INC | Common | 449778109 | 4,029,531 | 2,055,883 | SH | SOLE | 2,055,883 | 0 | 0 | ||
IOVANCE BIOTHERAPEUTICS INC | Common | 462260100 | 47,168,000 | 6,700,000 | SH | SOLE | 6,700,000 | 0 | 0 | ||
IVERIC BIO INC | Common | 46583P102 | 316,687,000 | 8,050,000 | SH | SOLE | 8,050,000 | 0 | 0 | ||
KRYSTAL BIOTECH INC | Common | 501147102 | 300,639,211 | 2,560,811 | SH | SOLE | 2,560,811 | 0 | 0 | ||
KURA ONCOLOGY INC | Common | 50127T109 | 32,850,900 | 3,105,000 | SH | SOLE | 3,105,000 | 0 | 0 | ||
KYMERA THERAPEUTICS INC | Common | 501575104 | 88,626,450 | 3,855,000 | SH | SOLE | 3,855,000 | 0 | 0 | ||
MADRIGAL PHARMACEUTICALS INC | Common | 558868105 | 349,999,881 | 1,515,151 | SH | SOLE | 1,515,151 | 0 | 0 | ||
MANNKIND CORP | Common | 56400P706 | 37,037,000 | 9,100,000 | SH | SOLE | 9,100,000 | 0 | 0 | ||
MARINUS PHARMACEUTICALS INC | Common | 56854Q200 | 34,209,000 | 3,150,000 | SH | SOLE | 3,150,000 | 0 | 0 | ||
MERSANA THERAPEUTICS INC | Common | 59045L106 | 20,973,750 | 6,375,000 | SH | SOLE | 6,375,000 | 0 | 0 | ||
MIRATI THERAPEUTICS INC | Common | 60468T105 | 200,722,202 | 5,555,555 | SH | SOLE | 5,555,555 | 0 | 0 | ||
MONTE ROSA THERAPEUTICS INC | Common | 61225M102 | 31,064,750 | 4,535,000 | SH | SOLE | 4,535,000 | 0 | 0 | ||
MOONLAKE IMMUNOTHERAPEUTICS | CLASS A ORD | 61559X104 | 87,975,000 | 1,725,000 | SH | SOLE | 1,725,000 | 0 | 0 | ||
NUVALENT INC | Common | 670703107 | 67,472,000 | 1,600,000 | SH | SOLE | 1,600,000 | 0 | 0 | ||
PMV PHARMACEUTICALS INC | Common | 69353Y103 | 19,155,600 | 3,060,000 | SH | SOLE | 3,060,000 | 0 | 0 | ||
ROIVANT SCIENCES LTD | Common | G76279101 | 58,526,113 | 5,806,162 | SH | SOLE | 5,806,162 | 0 | 0 | ||
SAREPTA THERAPEUTICS INC | Common | 803607100 | 529,985,734 | 4,627,888 | SH | SOLE | 4,627,888 | 0 | 0 | ||
SEAGEN INC | Common | 81181C104 | 338,653,771 | 1,759,606 | SH | SOLE | 1,759,606 | 0 | 0 | ||
SERES THERAPEUTICS INC | Common | 81750R102 | 11,975,000 | 2,500,000 | SH | SOLE | 2,500,000 | 0 | 0 | ||
SYNDAX PHARMACEUTICALS INC | Common | 87164F105 | 55,464,500 | 2,650,000 | SH | SOLE | 2,650,000 | 0 | 0 | ||
TALARIS THERAPEUTICS INC | Common | 87410C104 | 1,520,000 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
TANGO THERAPEUTICS INC | Common | 87583X109 | 5,444,800 | 1,640,000 | SH | SOLE | 1,640,000 | 0 | 0 | ||
ULTRAGENYX PHARMACEUTICAL INC | Common | 90400D108 | 34,597,500 | 750,000 | SH | SOLE | 750,000 | 0 | 0 | ||
UNITED THERAPEUTICS CORP | Common | 91307C102 | 642,382,279 | 2,909,999 | SH | SOLE | 2,909,999 | 0 | 0 | ||
VERRICA PHARMACEUTICALS INC | Common | 92511W108 | 17,044,949 | 2,954,064 | SH | SOLE | 2,954,064 | 0 | 0 | ||
XENON PHARMACEUTICALS INC | Common | 98420N105 | 188,650,000 | 4,900,000 | SH | SOLE | 4,900,000 | 0 | 0 |